Phenotypes Associated with This Genotype

Genotype
MGI:5008146

• Allelic Composition: Rictor^tm1.1Mgn/Rictor^tm1.1Mgn; Tg(Ins2-cre)25Mgn/0
• Genetic Background: involves: 129S6/SvEvTac * BALB/c * C57BL/6 * DBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

decreased pancreatic beta cell mass ( J:170129 )

• beta-cell mass is 28% lower than controls after adjusting for body size

• the reduction in beta cell mass is mainly due to a decrease in beta cell proliferation

• however, beta cell size is unaffected and islet number per pancreatic unit area is unchanged in mutants

abnormal pancreatic beta cell physiology ( J:170129 )

• pancreatic insulin content is about 50% less than controls

decreased pancreatic beta cell proliferation ( J:170129 )

• number of proliferating beta-cells is decreased by 26% compared to controls

decreased insulin secretion ( J:170129 )

• islets have approximately 70% lower insulin secretion in response to glucose than controls

• however, insulin sensitivity is normal

homeostasis/metabolism

abnormal glucose homeostasis ( J:170129 )

• total glucose excursion is higher compared to controls

decreased insulin secretion ( J:170129 )

• islets have approximately 70% lower insulin secretion in response to glucose than controls

• however, insulin sensitivity is normal

hyperglycemia ( J:170129 )

• mutants exhibit hyperglycemia beginning at 12 weeks of age

impaired glucose tolerance ( J:170129 )

• mutants show slower glucose clearance as indicated by elevated blood glucose concentrations at 15 and 30 min after an intraperitoneal glucose bolus

• impaired glucose tolerance is due to reduced pancreatic insulin content and impaired glucose-stimulated insulin secretion

cellular

decreased pancreatic beta cell proliferation ( J:170129 )

• number of proliferating beta-cells is decreased by 26% compared to controls